NSE · SUNPHARMA.NS
Sun Pharmaceutical Industries Limited
₹1,818.10+₹57.10 (+3.24%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the upper half of its reported 52-week range, 10.82% below the high.
Loading market information…
NSE · EMCURE.NS · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 09:02 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Emcure Pharmaceuticals Ltd.’s quoted price sits in the upper half of its reported 52-week range, 11.09% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Emcure Pharmaceuticals Ltd.’s forward annual dividend is ₹3.60 per share, paid annual. The forward yield is 0.19% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Emcure Pharmaceuticals Ltd.’s next earnings report is currently expected on Nov 3, 2026, with estimated earnings per share of ₹14.90. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Emcure Pharmaceuticals Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Emcure Pharmaceuticals Limited is committed to providing high-quality, cost-effective healthcare solutions to a global market. The company boasts a diverse product lineup spanning numerous medical fields, such as women's health (gynecology), anti-infectives, pain relief, nutritional supplements (vitamins, minerals, and nutrients), hematology, oncology, respiratory treatments, HIV antivirals, gastrointestinal remedies, anti-diabetics, neurological medications, and cardiovascular therapies. Notable brand names under their umbrella include Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym. Founded in 1981, Emcure Pharmaceuticals Limited is headquartered in Pune, India.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:02 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 | May 22, 2025 | ₹10.40+2.97% vs estimate | ₹21.16B+4.11% vs estimate |
|---|
| Q3 2024 | Feb 6, 2025 | ₹8.12-15.42% vs estimate | ₹19.63B+1.07% vs estimate |
|---|
| Q2 2024 | Nov 7, 2024 | ₹10.40+18.18% vs estimate | ₹20.02B+5.8% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹1,818.10+₹57.10 (+3.24%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the upper half of its reported 52-week range, 10.82% below the high.
₹4,605.50+₹25.50 (+0.56%)
Torrent Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 12.26% below the high.
₹1,355.00+₹10.00 (+0.74%)
Dr. Reddy's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 4.23% below the high.
₹1,373.50+₹15.50 (+1.14%)
Cipla Limited’s quoted price sits in the lower half of its reported 52-week range, 13.79% below the high.
₹2,498.70+₹29.40 (+1.19%)
Mankind Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 5.42% below the high.
₹1,675.60+₹15.70 (+0.95%)
Aurobindo Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 3.7% below the high.
₹2,009.90+₹20.00 (+1.01%)
Lupin Limited’s quoted price sits in the lower half of its reported 52-week range, 20.55% below the high.
₹2,314.80-₹24.20 (-1.03%)
Glenmark Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 8.77% below the high.
